We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Accelerating Biotherapeutic Charge Variant Analysis With a New iCIEF-MS Platform

Accelerating Biotherapeutic Charge Variant Analysis With a New iCIEF-MS Platform content piece image

In order to bring safe, effective protein therapeutics to market, in particular next generation molecules, biopharma development scientists need to analyze critical quality attributes at the intact protein level.

Key among these quality attributes are charge variants, which are commonly analyzed by imaged capillary isoelectric focusing (iCIEF). This technique has substantially impacted biopharmaceutical development through its high-separation resolution and minimal development time.

However, iCIEF lacks direct peak identification, requiring subsequent analysis across multiple systems. In this webinar, we introduce a new, innovative solution to separate and simultaneously identify acidic and basic charge variants for monoclonal antibodies, all within a 15-min assay.

By implementing the recently launched Blaze system, which uses a microchip-based icIEF separation with an on-chip ESI tip, and directly coupled to the SCIEX TripleTOF 6600 mass spectrometer, we will demonstrate how scientists can attain icIEF-MS mAb results, including separation and characterization of low abundance proteoforms, to accelerate the development of biotherapeutic drugs.

By attending this webinar you will learn:

  • Learn about the post-translational modifications that contribute to charge variants in protein therapeutics.
  • Learn about the role of iCIEF and mass spectrometry and their relative impact on biotherapeutic development.
  • Understand how coupling iCIEF and mass spectrometry unlocks new capabilities for characterizing quality attributes for biotherapeutics.
Maggie A. Ostrowski, PhD
Maggie A. Ostrowski, PhD
Director of Strategic Marketing Intabio, Inc